#United States #Atlanta #Cervical Cancer #HPV Testing #ACS Guidelines

New Cervical Cancer Screening Guidelines by ACS

In a significant advancement for women's health, the American Cancer Society (ACS) has announced updated guidelines for cervical cancer screenings, with a focus on improving detection and accessibility. Released on December 4, 2025, these new recommendations primarily address women at average risk and individuals with a cervix. The guidelines present two major changes: the introduction of self-collection of vaginal samples for Human papillomavirus (HPV) testing and updated guidance on when individuals can safely exit from cervical cancer screening.

According to Dr. Robert Smith, senior vice president, early cancer detection science at ACS, these modifications will not only help enhance compliance with screening but also reduce the risk of cervical cancer. The guidelines were developed based on the latest research and advancements in self-collection tools that make screening more accessible.

Cervical cancer screening has successfully reduced the incidence of the disease by over 50% since the 1970s; however, it is projected that 13,360 cases will be diagnosed in the U.S. this year, resulting in an estimated 4,320 deaths. These statistics underscore ongoing racial and socioeconomic disparities that need to be addressed.

Key Recommendations

The guidelines recommend that women and individuals at average risk begin screening at age 25 using primary HPV testing every five years, continuing until age 65. If HPV testing is not accessible, those in this age group should opt for co-testing with an HPV test and a cytology (Pap) test every five years, or cytology testing alone every three years.

For the first time, self-collection of vaginal specimens for HPV testing is being integrated into cervical cancer screenings. While clinician-collected samples are preferred, self-collection allows a broader demographic to participate in screenings. If a self-collected vaginal specimen tests negative for HPV, a repeat test is recommended after three years.

To discontinue screening, ACS suggests women and individuals with an average risk should have negative primary HPV tests or negative co-testing results at ages 60 and 65. If neither testing method is available, three consecutive negative cytology tests at the recommended intervals, with the final test at age 65, will suffice.

Understanding the Changes

These updated recommendations are a reflection of ACS's ongoing commitment to evolve their guidelines based on emerging scientific evidence. Recent approvals from the Food and Drug Administration (FDA) have validated the safety and efficacy of self-collection for HPV testing, making it a critical addition to the screening landscape.

It is important to note that ACS does not advise cervical cancer screening for women under age 25, or those over age 65 who have had sufficient prior screenings and are not considered high risk. Women who have undergone a hysterectomy (with cervix removal) are also exempt unless they have a history of severe precancerous conditions.

In late 2022, ACS established the National Roundtable on Cervical Cancer (ACS NRTCC), an initiative aimed at accelerating the goal of eliminating cervical cancer through better prevention strategies and increased screening uptake.

Alongside its advocacy work, the ACS Cancer Action Network (ACS CAN) continues to push for equitable access to cervical cancer screenings across various government levels. Lisa Lacasse, president of ACS CAN, highlighted the geographic disparities in cervical cancer incidences, particularly in rural populations, where individuals may face significant barriers to accessing healthcare services.

Additional Resources

ACS provides additional tools and resources, including a newly created patient page aimed at helping individuals better understand cervical cancer and their screening options. The comprehensive information shared within CA A Cancer Journal for Clinicians facilitates informed decisions regarding health and wellness.

With these updated guidelines, the ACS reaffirms its commitment to containing cervical cancer and improving healthcare accessibility.

For more detailed information, individuals can visit ACS's website or call their 24/7 helpline at 1-800-227-2345.